A Single Dose Pharmacokinetic Study of LY2409021 in Healthy Subjects to Bridge Formulations From Capsules to Commercial Tablets
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Adomeglivant (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 24 Mar 2018 Status changed to discontinued.
- 10 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 14 May 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.